Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
16 studies found for:    WAGR
Show Display Options
Rank Status Study
1 Recruiting Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Conditions: WAGR Syndrome;   Wilm's Tumor;   Aniridia;   Urogenital Abnormalities;   Mental Retardation
Intervention:
2 Completed
Has Results
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Intervention: Drug: WT1 Peptide Vaccine
3 Completed
Has Results
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Conditions: Leukemia, Acute Myelogenous (AML);   Leukemia, Acute Lymphocytic (ALL);   Leukemia, Chronic Myelogenous (CML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: WT1 Peptide-Pulsed Dendritic Cells;   Drug: Donor Lymphocytes;   Drug: IL-4;   Drug: KLH;   Drug: WT1 Peptides;   Drug: Endotoxin;   Drug: Diphenhydramine;   Drug: Acetaminophen
4 Completed
Has Results
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
Conditions: Myelodysplastic Syndrome (MDS);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Interventions: Biological: WT1:126-134;   Biological: PR1:169-177 Peptide;   Drug: GM-CSF (Sargramostim);   Biological: Montanide adjuvant
5 Recruiting Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
6 Completed Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: WT1 and PR1 Peptide Vaccine
7 Completed WT1 for the Detection of Minimal Residual Disease
Conditions: Leukemia;   Cancer
Intervention: Procedure: WT 1 Testing
8 Active, not recruiting Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myelocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: decitabine
9 Recruiting WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Biological: WT1 Analog Peptide Vaccine;   Biological: Sargramostim (GM-CSF);   Drug: lenalidomide
10 Unknown  Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases
Conditions: Denys-Drash Syndrome;   Frasier Syndrome;   Nephrotic Syndrome;   Wilms Tumor
Intervention:
11 Recruiting Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
12 Terminated Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines
Condition: Leukemia
Intervention: Biological: Autologous Dendritic Cells
13 Completed A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Condition: Acute Myeloid Leukemia
Interventions: Drug: conventional chemotherapy (AraC + Daunorubicin),;   Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
14 Active, not recruiting Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Biological: GM-K562 cell vaccine
15 Completed Study of the Pathophysiological Mechanisms Involved in Bleeding Events
Condition: Oculocerebrorenal Syndrome
Intervention: Other: Blood sample
16 Recruiting Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT
Condition: Acute Leukemia
Interventions: Biological: Genetically modified DCs combined with CIK cells;   Biological: Donor leukocyte infusions (DLI)

Indicates status has not been verified in more than two years